Molecular typing is predicated on molecular genetic screening and isn't nonetheless routinely accessible. Molecular subtypes and immunohistochemical surrogate markers from the tumors (HR, HER2, triple damaging) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and proliferation markers like Ki-67 could possibly